Researchers find NSAIDs help push stem cells into bloodstream prior to transplantation

March 14, 2013 by Bob Yirka report

(Medical Xpress)—A team of researchers at Indiana University's School of Medicine has found that giving meloxicam, a non-steroidal anti-inflammatory drug (NSAID), to people and baboons boosts the number of haematopoietic stem cells that enter the blood stream from bone marrow. This, the team writes in their paper they've had published in the journal Nature, may help cancer patients recover their ability to create new blood cells following chemotherapy.

Haematopoietic stem cells are precursors to blood cells that reside in bone marrow—they are harvested from healthy donors or from patients themselves prior to undergoing chemotherapy. Chemicals used to treat cancers such as leukemia or non-Hodgkin's lymphoma, destroy such stem cells, thus, patients who undergo treatment require a transplant of new cells from a donor or re-transplantation of cells harvested prior to treatment, so that their body can once again produce .

Currently a drug called filgrastim is used to cause more of the stem cells to leave the bone marrow and enter the blood stream where it can be collected for later transplantation. It works by inhibiting a lipid called prostaglandin E2, which among other things has been found to inhibit movement of stem cell movement from bone marrow to the . Unfortunately, not all patients respond well to filgrastim and that's why researchers have been looking for other drugs that can perform the same function. In this new effort, the researchers have found that NSAIDs (which include most aspirin-like pain relievers) are also able to coax stem cells from the bone marrow into the bloodstream. The team focused on meloxicam because it has the fewest negative side-effects of the group.

The research team has been able to study how meloxicam works with actual patients in field trials because it's a drug that has already been approved for use in patients for other purposes. They found that administering the drug to both people and increased the number of haematopoietic found in the blood and therefore may be a good replacement for patients who don't respond well to filgrastim. They also suspect that using both drugs might prove an even better approach as they've seen hints with baboon testing that doing so provides a synergistic effect. The team plans to next begin testing that approach in a new set of trials.

Explore further: New drug approved for lack of certain white blood cells

More information: Differential stem- and progenitor-cell trafficking by prostaglandin E2, Nature (2013) doi:10.1038/nature11929

Abstract
To maintain lifelong production of blood cells, haematopoietic stem cells (HSCs) are tightly regulated by inherent programs and extrinsic regulatory signals received from their microenvironmental niche. Long-term repopulating HSCs reside in several, perhaps overlapping, niches that produce regulatory molecules and signals necessary for homeostasis and for increased output after stress or injury. Despite considerable advances in the specific cellular or molecular mechanisms governing HSC–niche interactions, little is known about the regulatory function in the intact mammalian haematopoietic niche. Recently, we and others described a positive regulatory role for prostaglandin E2 (PGE2) on HSC function ex vivo. Here we show that inhibition of endogenous PGE2 by non-steroidal anti-inflammatory drug (NSAID) treatment in mice results in modest HSC egress from the bone marrow. Surprisingly, this was independent of the SDF-1–CXCR4 axis implicated in stem-cell migration. Stem and progenitor cells were found to have differing mechanisms of egress, with HSC transit to the periphery dependent on niche attenuation and reduction in the retentive molecule osteopontin. Haematopoietic grafts mobilized with NSAIDs had superior repopulating ability and long-term engraftment. Treatment of non-human primates and healthy human volunteers confirmed NSAID-mediated egress in other species. PGE2 receptor knockout mice demonstrated that progenitor expansion and stem/progenitor egress resulted from reduced E-prostanoid 4 (EP4) receptor signalling. These results not only uncover unique regulatory roles for EP4 signalling in HSC retention in the niche, but also define a rapidly translatable strategy to enhance transplantation therapeutically.

Related Stories

New drug approved for lack of certain white blood cells

August 30, 2012
(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

No survival advantage with peripheral blood stem cells versus bone marrow

October 19, 2012
(Medical Xpress)—Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted ...

Studying marrow, researchers accelerate blood stem cells

December 5, 2012
(Medical Xpress)—University of Rochester Medical Center scientists are testing a new approach to speed a patient's recovery of blood counts during a vulnerable period after a stem-cell transplant, according to a study published ...

Duke research team identifies a potent growth factor for blood stem cells

October 23, 2012
Duke Medicine researchers studying the interaction of blood stem cells and the niche where they reside have identified a protein that may be a long-sought growth factor for blood stem cells.

Distinct niches in bone marrow nurture blood stem cells

February 24, 2013
In research that could one day improve the success of stem cell transplants and chemotherapy, scientists have found that distinct niches exist in bone marrow to nurture different types of blood stem cells.

Recommended for you

Molecular hitchhiker on human protein signals tumors to self-destruct

July 24, 2017
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found.

Researchers develop new method to generate human antibodies

July 24, 2017
An international team of scientists has developed a method to rapidly produce specific human antibodies in the laboratory. The technique, which will be described in a paper to be published July 24 in The Journal of Experimental ...

A sodium surprise: Engineers find unexpected result during cardiac research

July 20, 2017
Irregular heartbeat—or arrhythmia—can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising ...

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

'Smart' robot technology could give stroke rehab a boost

July 19, 2017
Scientists say they have developed a "smart" robotic harness that might make it easier for people to learn to walk again after a stroke or spinal cord injury.

Engineered liver tissue expands after transplant

July 19, 2017
Many diseases, including cirrhosis and hepatitis, can lead to liver failure. More than 17,000 Americans suffering from these diseases are now waiting for liver transplants, but significantly fewer livers are available.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.